Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx is attractive because it is a commercial-stage biopharmaceutical company built around tenapanor, a differentiated sodium transport inhibitor approved for IBS-C and CKD-related hyperphosphatemia, giving it two large, underserved markets with persistent unmet need. The thesis is strengthened by the prospect of expanding Ibsrela into CIC, a much larger US population than IBS-C, with >50% of patients dissatisfied with current options, while Xphozah addresses poor adherence in dialysis patients burdened by 7-10 phosphate binder pills per day and 57% skipping therapy at least once in the past month. Despite reimbursement headwinds and a recent guidance revision in 2Q26, the company’s >95% gross margin supports patient assistance, specialty-pharmacy execution, and continued prescription growth, making the setup primarily an execution and commercial uptake story.

Ardelyx is exposed to substantial regulatory risk, as approval pathways may require additional data or longer studies, and any label limitations could curb adoption of IBSRELA and XPHOZAH. Commercial execution also remains uncertain, since failure to meet or exceed expectations could pressure shares, while reimbursement pricing changes could directly weaken product economics and market traction. Competitive threats from generic players and established names such as AMGN, OPKO, Shield Therapeutics and AKBA add further uncertainty, especially because new entrants are likely to emerge over time.